SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

AMC Robotics Corp. engages in developing and deploying AI-enabled robotics and smart security solutions, especially for warehouse automation, enterprise security, robotics patrol/incident-response and logistics automation. The company is headquartered in New York, NY.

AMC Robotics Corp.

AMCI is trending due to excitement around its AI-powered robotics technology following its AlphaVest merger. Community members are discussing potential short squeezes and comparing it to other high-flying stocks like SMX, while also noting its low float and volatility.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending amidst discussions around its future financial guidance and potential acquisitions, with the community actively debating the company's direction and whether it represents a long-term investment opportunity. Some traders are weighing in on option strategies, while others express frustration with the stock's perceived lack of movement. Broader market narratives, including the performance of other pharmaceutical stocks and potential impacts from regulatory actions, are also influencing the conversation.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is trending downwards, with the community citing concerns around debt, dilution, and a potential AI bubble as reasons for the decline. Some traders are calling for a continued sell-off, while others believe the dip represents a buying opportunity based on the company's long-term potential in AI data centers. Overall sentiment is mixed, with many expressing frustration over recent losses.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid speculation and rumors of potential rescheduling of cannabis, fueled by comments from political figures. The community is buzzing with anticipation of an executive order, with many believing it could trigger a significant short squeeze. Discussions also include Tilray's profitability and its potential to benefit from broader cannabis market developments.

Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.

Biodexa Pharmaceuticals Plc - ADR

Biodexa Pharmaceuticals Plc

BDRX is trending due to a circuit breaker halt and resulting momentum, with community members citing its low float as a catalyst for potential further gains. Discussions revolve around potential price targets, with some suggesting the stock could reach significantly higher values. The stock is also appearing on top gainers lists, attracting attention from traders looking for quick profits.

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. It engages in the discovery of therapies designed to treat immune-mediated diseases. The company was founded by Thomas A. Jordan and John E. Dowling on August 13, 2004 and is headquartered in Lexington, MA.

Aldeyra Therapeutics Inc

ALDX is trending due to the FDA's extended review timeline for its dry eye disease drug, Reproxalap, with a new PDUFA date in March 2026. While the extension triggered a price drop, the community is debating whether this is a procedural delay or indicates deeper issues with the application, with some speculating about approval being priced in. Bullish sentiment remains due to expectations of eventual approval and potential acquisition by AbbVie.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is gaining traction as a Solana-based meme coin with a strong and positive community, attracting attention as a potentially resilient asset within the SOL ecosystem. Discussions highlight its locked liquidity and focus on community-driven growth, with some viewing it as a way to benefit from the overall expansion of the Solana ecosystem.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid's stock is trending amidst mixed sentiment, with some traders expressing frustration over losses and a lack of a permanent CEO while others point to positive developments like the Gravity SUV and potential partnerships. Community discussions revolve around the company's cash burn, production targets, and the impact of the recent reverse stock split. Some investors are closely watching for news that could catalyze a turnaround, while others are comparing Lucid's potential to that of its competitors.

Nektar Therapeutics is a biotechnology company, which engages in the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. It also focuses on immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit. The company was founded in 1990 and is headquartered in San Francisco, CA.

Nektar Therapeutics

Nektar Therapeutics is trending amid community excitement following Phase 2b results for its alopecia areata drug, rezpegaldesleukin, with discussions around its safety profile compared to existing treatments. Community members are speculating on potential analyst upgrades and are awaiting news from an LLY trial, as well as Phase 2b results for AD in Q1, signaling optimism for the company's pipeline. Broader interest is focused on whether these developments could lead to a potential acquisition or a significant boost in its market valuation.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending as the stock experiences significant volatility, with community members debating whether recent price drops represent a buying opportunity or a sign of deeper issues. Discussions include the company's growth potential in the AI and data center space, its relationship with major players like Microsoft and Meta, and concerns about market conditions.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$MRBK Meridian Bank reports Q2 EPS 30c, consensus 31c  
 
Total assets at June 30, 2024 were $2.4B, compared to $2.3B at March 31, 2024 and $2.2B at June 30, 2023. Net interest margin was 3.06% for the second quarter of 2024, with a loan yield of 7.31%. Reports book value per common share $14.51 and tangible book value per common share $14.17. Reports common tier 1 risk-based capital ratio 9.84%. Christopher Annas, CEO commented: &quot;Our second quarter earnings showed significant improvement from the first quarter, increasing by 24.3% to $3.3M, or $0.30 per share.  
 
Key highlights include a steady net interest margin at 3.06% for the quarter and a quarterly profit in our mortgage segment. Total loan growth in the first half was 6.5% as we continue to bring on new relationships and take advantage of market disruption. Real estate loan growth is particularly strong in residential and multi-family, which are both in high demand. The Philadelphia metro region remains healthy, with a continued shortage of homes for sale. A recent comment from DR Horton highlighted that the US needs 5 million more homes nationally to meet demand, a deficiency that is evident in our region.  
 
Private equity&#39;s significant ownership and rental of homes nationally contributes to this problem. Despite these challenges our volume has improved from 2023, and if rates come down the demand could strengthen. Meridian continues to gain market share in our region. While navigating the rate rise has presented some obstacles, our core businesses remain healthy. We are excited about our prospects and the generally stable economic landscape.&quot;

Will

StockTwits Web

Meridian Corp

 Meridian Bank reports Q2 EPS 30c, consensus 31c  
 
Total assets at June 30, 2024 were $2.4B, compared to $2.3B at March 31, 2024 and $2.2B at June 30, 2023. Net interest margin was 3.06% for the second quarter of 2024, with a loan yield of 7.31%. Reports book value per common share $14.51 and tangible book value per common share $14.17. Reports common tier 1 risk-based capital ratio 9.84%. Christopher Annas, CEO commented: "Our second quarter earnings showed significant improvement from the first quarter, increasing by 24.3% to $3.3M, or $0.30 per share.  
 
Key highlights include a steady net interest margin at 3.06% for the quarter and a quarterly profit in our mortgage segment. Total loan growth in the first half was 6.5% as we continue to bring on new relationships and take advantage of market disruption. Real estate loan growth is particularly strong in residential and multi-family, which are both in high demand. The Philadelphia metro region remains healthy, with a continued shortage of homes for sale. A recent comment from DR Horton highlighted that the US needs 5 million more homes nationally to meet demand, a deficiency that is evident in our region.  
 
Private equity's significant ownership and rental of homes nationally contributes to this problem. Despite these challenges our volume has improved from 2023, and if rates come down the demand could strengthen. Meridian continues to gain market share in our region. While navigating the rate rise has presented some obstacles, our core businesses remain healthy. We are excited about our prospects and the generally stable economic landscape."